Results from a Phase 3 clinical trial, JAVELIN Bladder 100, evaluating Pfizer (NYSE:PFE) and alliance partner Merck KGaA’s (OTCPK:MKGAY) Bavencio (avelumab) for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress in induction chemo met the primary endpoint of overall survival (OS).
The data will be submitted for presentation at a future medical conference and will be shared with regulatory authorities.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.